EUVIMEDEUVIMED entdecken
Crossref

Phenotype and renal outcomes of patients with congenital arginine vasopressin resistance

Min-Hua Tseng, Chih-Chien Sung, Chih-Jen Cheng, Jeng-Daw Tsai, Jhao-Jhuang Ding, Shih-Hua Lin

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Min-Hua Tseng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Receptors, Vasopressin, Mutation, Arginine Vasopressin. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital, Tri-Service General Hospital, Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis The clinical phenotype and long-term outcomes of patients with congenital arginine vasopressin-resistance (AVP-R) have not been well evaluated. This study investigated the clinical features, treatment modalities and renal outcomes of patients with AVP-R.

Methods

Twenty-seven patients (male:female = 21:6, mean age = 22 ± 17 years) with genetically confirmed AVP-R from 18 unrelated Taiwanese families were included. Genomic DNA extracted from blood leukocytes was analyzed for AVPR2 and AQP2 mutations. Clinical presentations, laboratory findings, management and follow-up data, including analyses of renal function changes, were evaluated.

Results

Seventeen patients from 12 X-linked recessive families harbored 11 different AVPR2 mutations, including three novel small deletions and two large deletion mutations. Eight patients from five autosomal recessive (AR) families harbored three different AQP2 mutations (Q57P, G100V, V168Rfs*32) and two patients from one autosomal dominant (AD) family harbored a novel AQP2 R253Dfs*82 mutation. The median ages at onset of polyuria and polydipsia and at clinical diagnosis of AVP-R were 0.7 (range 2 months–2.5 years) and 11.7 (range 0.7–21.5) years, respectively. Three-quarters of patients were treated with oral hydrochlorothiazide alone or combined with amiloride, and one-third received indomethacin. Intrafamilial phenotypic heterogeneity was observed in one family harboring the AVPR2 F178L mutation. Seven patients exhibited persistent non-obstructive hydroureteronephrosis. At a median follow-up of 16.6 (2.2–25.7) years, seven patients (26%) had progressed to chronic kidney disease (CKD, stage III–V), of whom three (AVPR2 mutation = 2, AD AQP2 R253Dfs*82 = 1) were dependent on dialysis. An earlier age of onset, higher serum osmolality, larger daily urine volume and hydroureteronephrosis at first presentation were independent risk factors for CKD progression.

Conclusions

Non-obstructive hydroureteronephrosis is a common complication of congenital AVP-R. CKD frequently develops in patients with phenotypically severe congenital AVP-R, independent of AVPR2 or AQP2 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, VasopressinMutationArginine VasopressinHumansMaleFemalePhenotypeAdolescentChildAdultYoung AdultChild, PreschoolInfantAquaporin 2PrognosisFollow-Up StudiesGlomerular Filtration RateKidney Failure, ChronicPedigree

Stichwörter der Autor:innen

AVP-RAVPR2aquaporin 2mutations

Substanzen

Receptors, VasopressinAquaporin 2AVPR2 protein, humanArginine VasopressinAQP2 protein, human

Autor:innen und Institutionen

  • Division of Nephrology, Department of Pediatrics, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
  • Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
  • Department of Pediatrics, Mackay Memorial Hospital, Taipei Medical University, Taipei, Taiwan.
  • Department of Pediatrics, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.

Förderung

  • Chang Gung Memorial Hospital
  • Tri-Service General Hospital
  • Ministry of Science and Technology

Zitieren

APA

Tseng, M. H., Sung, C. C., Cheng, C. J., Tsai, J. D., Ding, J. J., & Lin, S. H. (2025). Phenotype and renal outcomes of patients with congenital arginine vasopressin resistance. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf218

Vancouver

Tseng MH, Sung CC, Cheng CJ, Tsai JD, Ding JJ, Lin SH. Phenotype and renal outcomes of patients with congenital arginine vasopressin resistance. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf218

BibTeX
@article{Tseng2025,
  author = {Tseng, Min-Hua and Sung, Chih-Chien and Cheng, Chih-Jen and Tsai, Jeng-Daw and Ding, Jhao-Jhuang and Lin, Shih-Hua},
  title = {Phenotype and renal outcomes of patients with congenital arginine vasopressin resistance},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf218}
}
Kostenlos starten →